MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. CEO Ofer Gonen will engage in a fireside chat on September 10, 2024, at 3:30 p.m. ET.

The discussion, hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research, will be available via live webcast. Investors and interested parties can access the webcast through a provided link or on MediWound's website under the Events & Presentations page in the Investors section.

This presentation offers an opportunity for investors to gain insights into MediWound's latest developments and future prospects in the field of next-generation enzymatic therapeutics for tissue repair.

YAVNE, Israel, Sept. 03, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research, on Tuesday, September 10, 2024 at 3:30 p.m. ET at the H.C. Wainwright 26^th Annual Global Investment Conference.

A live webcast of the event will be accessible both here and on MediWound’s website, under the Events & Presentations page of the Investors section.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of rapid and effective biologics that improve existing standards of care and patient experiences, while reducing costs and unnecessary surgeries.

MediWound’s first drug, NexoBrid^®, is an FDA and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, which can significantly reduce surgical interventions. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline, including the company’s lead drug under development, EscharEx^®. EscharEx is a Phase III-ready biologic for the debridement of chronic wounds, offering significant potential advantages over the dominant $360+ million product and an opportunity to expand the market.

For more information visit www.mediwound.com and follow the Company on LinkedIn.

MediWound Contacts:
Hani Luxenburg	Daniel Ferry
Chief Financial Officer	Managing Director
MediWound Ltd.	LifeSci Advisors, LLC
ir@mediwound.com	daniel@lifesciadvisors.com
Media Contact:
Ellie Hanson
FINN Partners for MediWound
ellie.hanson@finnpartners.com
+1-929-588-2008

FAQ

When is MediWound (MDWD) presenting at the H.C. Wainwright Global Investment Conference?

MediWound (MDWD) is presenting at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024 at 3:30 p.m. ET.

Who will be representing MediWound (MDWD) at the H.C. Wainwright conference?

Ofer Gonen, the Chief Executive Officer of MediWound (MDWD), will be representing the company at the H.C. Wainwright conference.

How can investors access MediWound's (MDWD) presentation at the H.C. Wainwright conference?

Investors can access MediWound's (MDWD) presentation via a live webcast available through a provided link or on MediWound's website under the Events & Presentations page in the Investors section.

What is the focus of MediWound's (MDWD) business?

MediWound (MDWD) is a global leader in next-generation enzymatic therapeutics for tissue repair.